Ordering Recommendation

Monitor for development of EGFR T790M drug-resistant mutation in patients administered tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant non-small cell lung cancer. Monitor response to therapy and disease progression in patients treated with EGFR T790M-specific TKIs.

Mnemonic

EGFR T790M

Methodology

Polymerase Chain Reaction

Performed

Varies

Reported

7-12 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Whole blood in two 10 mL Cell-Free DNA (cfDNA) BCT Tubes (ARUP Supply #52358) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. Also acceptable: CSF collected in a sterile container.

Specimen Preparation

Whole Blood: Transport 20 mL whole blood. (Min: 16 mL)
CSF: Transport 4 mL CSF. (Min: 4 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

FFPE tissue. Whole Blood collected in non-cfDNA BCT tubes.

Remarks
Stability

Whole Blood: Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
CSF: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: Unacceptable

Reference Interval

Interpretive Data

Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81235

Components

Component Test Code* Component Chart Name LOINC
2012869 EGFR T790M Result 55769-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

EGFR T790M Mutation Detection in Circulating Tumor DNA by Digital Droplet PCR